Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027599 · ClinicalTrials.gov registry record · Phase 2
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00027599: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00027599 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027599, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer. Biological therapies such as APC8015 use different ways to stimulate the immune system and stop cancer cells from growing. Monoclonal antibodies such as bevacizumab can locate tumor cells and kill them without harming normal cells. Combining monoclonal antibody therapy with biological therapy may kill more cancer cells.
Interventions
- BIOLOGICAL bevacizumab
- BIOLOGICAL sipuleucel-T
- PROCEDURE in vitro-treated peripheral blood stem cell transplantation
- BIOLOGICAL therapeutic autologous dendritic cells
- BIOLOGICAL prostatic acid phosphatase-sargramostim fusion protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2001-12 |
| Phase | Phase 2 |
What the finished NCT00027599 record still lists
NCT00027599 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 5 interventions - of which bevacizumab is the first listed.
NCT00027599 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00027599 about?
NCT00027599 is a clinical study titled "APC8015 and Bevacizumab in Treating Patients With Prostate Cancer". Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer. Biological therapies such as APC8015 use different ways to stimulate the immune system and stop cancer cel...
What is the current status of trial NCT00027599?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2001-12.
What interventions are being tested in trial NCT00027599?
The interventions under investigation include: bevacizumab (BIOLOGICAL), sipuleucel-T (BIOLOGICAL), in vitro-treated peripheral blood stem cell transplantation (PROCEDURE), therapeutic autologous dendritic cells (BIOLOGICAL), prostatic acid phosphatase-sargramostim fusion protein (BIOLOGICAL).
Who is sponsoring clinical trial NCT00027599?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00027599's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia